Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues1 adds value to the current literature, and we would like to share our comments.

New options for testing and treating some of the most common sexually transmitted diseases are becoming available, a trend ...

Background Azithromycin mass drug administration (MDA) to ages 1–59 months can reduce childhood mortality; however, more ...

The European regulator’s anniversary year featured first-in-class therapies, rare-disease advances, safety warnings, and new ...

Elexacaftor/tezacaftor/ivacaftor use is linked to long-term decreases in chronic respiratory therapies in patients with cystic fibrosis.

Many health insurance plans are required by the Affordable Care Act (ACA) to cover certain STD screenings without ...

New options for testing and treating some of the most common sexually transmitted diseases are becoming available, a trend ...

4 University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the) 5 Kinshasa School of Public Health, Kinshasa, Congo (the Democratic Republic of the) Introduction Maternal and neonatal ...